Navigation Links
A Milky Alternative to Alzheimer Drug

There is a new alternative to the Alzheimer drug in the form of a milkshake. This milkshake style medicine seems to feed the brain cell starved by the damages of the Alzheimer disease . It is one among the four experimental drugs awaiting large scale testing against the brain destroying disease.

The milkshake drug, called Ketasyn, is a new approach to treating dementia. It centers on latest research suggesting diabetic-like changes in brain cells' ability to use sugar for energy play a role in at least some forms of Alzheimer's.

Special fatty acids in Ketasyn present an alternate food source to energies those hungry neurons, according to the researchers at the international Alzheimer's meeting here Monday. Adding the Ketasyn to the regular medicine showed a small but important improvement in mental functioning. This was experience by people who do not carry the Alzheimer's gene called ApoE4. This improvement was seen in half of the 150 people tested with the new alternative.

The milkshake drug Ketasyn follows the principle that when someone fasts, the body lives off stored fat. Ketasyn contains fatty acids that the liver metabolizes into substances called ketones, similar to what's produced during a fast. Brain cells can use ketones in place of sugar for energy.

That's also similar to the high-fat, low-protein ketogenic diet sometimes used for children with severe epilepsy. Manufacturer Accera is currently hunting funding for a Phase III study, and exploring different formulations for epilepsy and other brain disorders.

"We see this as a co-therapy," not a way to stop Alzheimer's, cautioned Dr. Lauren Constantini, a former Harvard scientist now with the company Accera Inc. that is developing the drug.

To stop Alzheimer's brain decay, most scientists are depending on drugs that promise to prevent sticky goo called beta-amyloid from clogging up patients' brains. And Monday did not bri ng good news on that front: The first of those amyloid blockers to make it to large-scale, Phase III testing has hit a hurdle, and scientists will have to wait until at least month's end to learn if the much-anticipated drug Alzhemed really works.

The problem is statistical, said lead researcher Dr. Paul Aisen of Georgetown University: Hospital-to-hospital differences in other medication use among the study's 1,000 participants prevent an immediate clear comparison of Alzhemed's role. Working with the Food and Drug Administration, researchers are adjusting for those variations, Aisen told the Alzheimer's Association's dementia prevention meeting.


'"/>




Related medicine news :

1. Prince Charles lends support to Alternative Medicine
2. Alternative medicine more popular among HIV positive patients
3. Complementary and Alternative medicine
4. Alternative therapies popular with Parkinsons patients
5. Alternative to blood Transfusions
6. Alternative Therapy in HIV Patients
7. An Alternative to Warfarin
8. Another Alternative For Diabetics On Insulin
9. The Use Of Alternative Medicine On The Rise
10. Heart Patients Use Alternative Medicine
11. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2016)... ... 2016 , ... Spartan Bioscience today introduced the Spartan Cube, ... , The Cube is exceptionally small—it takes up the space of a coffee ... any space, whether in a hospital, doctor’s office, or pharmacy. , The device’s ...
(Date:5/31/2016)... ... May 31, 2016 , ... The successful implementation of ... their laboratories as well. However, laboratories have different challenges compared to manufacturing environments. ... operations in the lab, METTLER TOLEDO has developed the Lean Lab Checklist . ...
(Date:5/31/2016)... , ... May 31, 2016 , ... The Global ... today released ten predictions on the future of wellness, travel, spa and beauty in ... travel, spa and beauty companies to leading economists and researchers - to forecast where ...
(Date:5/31/2016)... ... ... In his latest video, renowned AstroNumerologist Jesse Kalsi reveals ... candidate Donald Trump as an example, Kalsi describes the way AstroNumerology conveys the ... numbers up,” says Kalsi. “It is about looking at each individual number, since ...
(Date:5/31/2016)... ... ... The Orthopaedic Research and Education Foundation (OREF) is pleased to announce the ... his term as president in March, succeeding John J. Callaghan, MD, who remains on ... F. Kyle, MD, will serve as chair, corporate development, succeeding Thomas P. Schmalzried, MD, ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 According to the ... is driving ambulatory blood pressure monitoring system market growth. ... their ability to respond to different pressure rates, leading ... lead to various cardiovascular disorders such as heart failure, ... diseases are growing in prevalence each year. WHO estimates ...
(Date:5/27/2016)... -- Amarantus BioScience Holdings, Inc. (OTCQX: ... Medicine, Neurology and Orphan Diseases, today announced that President & CEO ... investor conferences: SeeThru Equity MicroCap Conference   ... York City , NY When: Tuesday, May 31 ...   Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
Breaking Medicine Technology: